The goal of this proposal is to explore ways to generate a novel AAV vector to overcome the barrier of pre- existing vector neutralizing antibodies (NAbs) to achieve efficient gene transfer in vivo. In vivo delivery of AAV vectors has shown promise in a variety of pre-clinical and clinical models of inherited disorders. The major challenges to date involve host immune responses and poor transduction efficiency due to limited vector tropism and poor delivery of the vector to the target cell. AAV serotype 8 (AAVS) has been identified as the best Clinical Candidate vector for liver-directed gene transfer and is currenfiy being evaluated in a human clinical trial for gene therapy of hemophilia B. Much is still being learned about host-vector immune interactions such as the effect of innate immunity and activation of T cells and B cells against the vector and its transgene product. One of the most important aspects of host immunity is the impact of neutralizing antibodies (NAb) on transduction efficiency. NAb against the AAV vector capsid results in substantial reduction in transducfion when administered systemically, as demonstrated in preclinical studies in animal models and in human clinical trials. We have characterized the threshold titer of pre-existing NAb that is compromising to AAVS gene transfer in nonhuman primates. Pre-existing NAb fiters in excess of 1:10 substantially diminish hepatocyte transduction at the dose of 3x10^^ genonne copies/kg. Based on our survey in human samples, we predict that 25% of humans in the USA will not be suitable for systemic delivery of AAVS vector. Engineered vectors that can escape neutralization would provide a more general and effective solufion. In this project, we will employ mulfiple approaches guided by AAV structures with the ultimate aim to generate an "AAVS-prime" (AAVS') vector that retains the high liver tropism of AAVS and is more resistant to neutralization in humans.
Many inherited metabolic diseases, such as OTC deficiency, are lacking effective treatments. Adeno- associated vector-mediated hepatic gene therapy has the potential to provide an alternative to cure or treat these life-threatening disorders. This project aims to developing improved vectors to overcome the barriers to achieving efficient therapeutic effects.
|Yang, Yang; Wang, Lili; Bell, Peter et al. (2016) A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 34:334-8|
|Bissig-Choisat, Beatrice; Wang, Lili; Legras, Xavier et al. (2015) Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun 6:7339|
|Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87|
|Mikals, Kyle; Nam, Hyun-Joo; Van Vliet, Kim et al. (2014) The structure of AAVrh32.33, a novel gene delivery vector. J Struct Biol 186:308-17|
|Mays, Lauren E; Wang, Lili; Lin, Jianping et al. (2014) AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther 22:28-41|
|Bryant, Laura M; Christopher, Devin M; Giles, April R et al. (2013) Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 24:55-64|
|Zhong, Li; Malani, Nirav; Li, Mengxin et al. (2013) Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther 24:520-5|
|Wilson, James M; Shchelochkov, Oleg A; Gallagher, Renata C et al. (2012) Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Mol Genet Metab 105:263-5|
|Wang, Lili; Wang, Huan; Bell, Peter et al. (2012) Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. Hum Gene Ther 23:533-9|
|Wang, Lili; Morizono, Hiroki; Lin, Jianping et al. (2012) Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. Mol Genet Metab 105:203-11|
Showing the most recent 10 out of 23 publications